[A21-145] Pembrolizumab (breast cancer, triple-negative, locally recurrent/metastatic, in combination with chemotherapy) - Benefit assessment according to §35a Social Code Book V
Last updated 05.05.2022
Project no.:
A21-145
Commission:
Commission awarded on 16.12.2021 by the Federal Joint Committee (G-BA).
Report type:
Dossier assessment
Status:
Commission completed
Department/Division:
Drug Assessment
Topic:
Cancer
Adult patients with locally recurrent unresectable or metastatic triple-negative breast cancer whose tumours express PD-L1 (combined positive score ≥ 10) and who have not received prior chemotherapy for metastatic disease
Hint of non-quantifiable added benefit
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.
Federal Joint Committee (G-BA)
2022-05-05 A G-BA decision was published.